Protagonist Therapeutics, Inc. (PTGX) Rating Lowered to Hold at Zacks Investment Research

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

A number of other research firms have also recently commented on PTGX. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BTIG Research initiated coverage on Protagonist Therapeutics in a report on Friday, July 21st. They set a “buy” rating and a $36.00 price target for the company.

Protagonist Therapeutics (NASDAQ PTGX) traded down 1.97% on Wednesday, reaching $15.93. The company’s stock had a trading volume of 203,807 shares. The company has a 50-day moving average price of $16.87 and a 200 day moving average price of $12.82. Protagonist Therapeutics has a 12 month low of $8.00 and a 12 month high of $26.36. The company’s market cap is $269.25 million.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.70).

TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/20/protagonist-therapeutics-inc-ptgx-rating-lowered-to-hold-at-zacks-investment-research.html.

In other Protagonist Therapeutics news, insider Richard S. Shames sold 2,017 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Richard S. Shames sold 3,687 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $14.31, for a total value of $52,760.97. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,716 shares of company stock valued at $169,288.

A number of institutional investors and hedge funds have recently modified their holdings of PTGX. Rhumbline Advisers acquired a new position in Protagonist Therapeutics in the 2nd quarter worth about $114,000. Teachers Advisors LLC increased its stake in shares of Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after buying an additional 6,757 shares during the period. Northern Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics in the second quarter valued at about $188,000. California State Teachers Retirement System increased its stake in shares of Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after buying an additional 3,812 shares during the period. 48.04% of the stock is owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therape

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

A number of other research firms have also recently commented on PTGX. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BTIG Research initiated coverage on Protagonist Therapeutics in a report on Friday, July 21st. They set a “buy” rating and a $36.00 price target for the company.

Protagonist Therapeutics (NASDAQ PTGX) traded down 1.97% on Wednesday, reaching $15.93. The company’s stock had a trading volume of 203,807 shares. The company has a 50-day moving average price of $16.87 and a 200 day moving average price of $12.82. Protagonist Therapeutics has a 12 month low of $8.00 and a 12 month high of $26.36. The company’s market cap is $269.25 million.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.70).

TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/10/20/protagonist-therapeutics-inc-ptgx-rating-lowered-to-hold-at-zacks-investment-research.html.

In other Protagonist Therapeutics news, insider Richard S. Shames sold 2,017 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Richard S. Shames sold 3,687 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $14.31, for a total value of $52,760.97. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,716 shares of company stock valued at $169,288.

A number of institutional investors and hedge funds have recently modified their holdings of PTGX. Rhumbline Advisers acquired a new position in Protagonist Therapeutics in the 2nd quarter worth about $114,000. Teachers Advisors LLC increased its stake in shares of Protagonist Therapeutics by 71.4% in the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after buying an additional 6,757 shares during the period. Northern Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics in the second quarter valued at about $188,000. California State Teachers Retirement System increased its stake in shares of Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Protagonist Therapeutics by 19.5% in the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after buying an additional 3,812 shares during the period. 48.04% of the stock is owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply